RIBOLIFE-B(06938.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
RIBOLIFE-B
06938.HK
Suzhou Ribo Life Science Co., Ltd. researches and develops small nucleic acid drugs for treating cardiovascular, metabolic, renal, liver, and other diseases. It develops RBD4059 for treating thrombotic diseases; RBD5044 for treating hypertrigly ceridemia; RBD7022 for treating Hypercho lesterolemia; RBD1016 for treating CHB and CHD that are in Phase II clinical trials. The company also develops RBD7007 and RBD2080 for treating renal diseases; and RBD1119 for treating thrombotic diseases, which are in Phase I clinical trials.
1.330 T
06938.HKMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Suzhou Ribo Life Science Receives Phase II Trial Approval for RBD5044 in China

    Suzhou Ribo Life Science Co., Ltd. has received approval from China's National Medical Products Administration to advance its RBD5044 Injection into Phase II clinical trials. This siRNA therapy targets APOC3, a protein linked to lipid metabolism, and aims to treat complications from hypertriglyceridemia. However, the company cautions that successful development and commercialization are not guaranteed.

    Reuters·
    HK
    06938
    +0.06%
    Reuters·
    HK
    06938
    +0.06%

    Top 10 HK Stock Losers (1.14)

    DEEWIN(02418) fell 23.56%, with a trading turnover 18.9 Million HKD, and a year-to-date fell 63.6%. DALIPAL HLDG(01921) fell 15.58%, with a trading turnover 51.4 Million HKD, and a year-to-date fell 11.3%. IB SETTLEMENT(00147) fell 11.73%, with a trading turnover 6.8 Million HKD, and a year-to-date rose 0%.

    Top Gainers & Losers·
    HK
    02418
    -9.82%
    HK
    01921
    -2.02%
    HK
    00147
    +14.46%
    Top Gainers & Losers·
    HK
    02418
    -9.82%
    HK
    01921
    -2.02%
    HK
    00147
    +14.46%

    Soochow Securities Keeps Their Buy Rating on Suzhou Ribo Life Science Co., Ltd. Class H (6938)

    Soochow Securities has maintained a Buy rating on Suzhou Ribo Life Science Co., Ltd. Class H (6938) with a price target of HK$114.60. The shares closed at HK$80.90. The overall analyst consensus suggests a Moderate Buy rating with an average price target of HK$114.60.

    Tip Ranks·
    HK
    06938
    +0.06%
    Tip Ranks·
    HK
    06938
    +0.06%

    Hong Kong Stock Movement Quick Report: SYNAGISTICS surged 30%, tech stocks lead the rise, KAISUN HOLDINGS fell 16%

    Hong Kong stock market overview in the past hour: The Hong Kong stock market has shown a significant sector rotation in the past hour, with technology and pharmaceutical stocks performing particularly well. Capital flow has concentrated on small-cap stocks and thematic stocks, and market sentiment is relatively active. Overall, there is a clear differentiation between strong and weak stocks, with some individual stocks seeing significant gains while others are under pressure. Short-term enthusiasm is high, and volatility is large. The stock with the biggest movement in the past hour is SYNAGISTICS, which surged 30.69%, becoming the market focus. The stock rapidly increased in a short time, with noticeable capital inflow, driving the activity of related sectors. Strong stocks: 1. INSILICO: up 20.11%, driven by short-term capital, with high market attention. 2. APT SATELLITE: up 19.96%, driven by sector rotation, with noticeable capital inflow. 3. FOURTH PARADIGM: up 19.06%, strong technical performance, with high short-term enthusiasm. 4. OPTIMA AUTO: up 18.42%, positive market sentiment, with capital chasing. 5. RIMAG GROUP: up 17.25%, outstanding performance in the pharmaceutical sector, with capital inflow. 6. C STRATEGIC TEC: up 16.84%, driven by short-term capital, with high market attention. 7. JINXUN RESOURCE: up 16.35%, strong performance in resource stocks, with noticeable capital inflow. 8. CDAYENONFER: up 15.70%, active performance in the non-ferrous metal sector, with capital chasing. 9. GCL NEWENERGY: up 15.22%, outstanding performance in the new energy sector, with capital inflow. 10. KINGSOFT CLOUD: up 15.20%, strong performance in technology stocks, with high market attention

    HK Stock Movers Tracker·
    HK
    03636
    -2.06%
    HK
    06938
    +0.06%
    HK Stock Movers Tracker·
    HK
    03636
    -2.06%
    HK
    06938
    +0.06%

    The Hong Kong stock market is performing well, with three new stocks being popular; MINIMAX has doubled compared to its listing price

    Hong Kong stocks fluctuated positively today, with the market focusing on the U.S. non-farm payroll data and Trump's tariff ruling. The Hang Seng Index closed at 26,231 points, up 82 points, with a turnover of HKD 245.13 billion. New stocks performed well, with MINIMAX-WP closing at HKD 345, up 109.1%; RIBOLIFE-B closing at HKD 82.1, up 41.6%; and JINXUN RESOURCE closing at HKD 37.8, up 26%. Net inflow of southbound funds was HKD 6.815 billion

    AASTOCKS·
    HK
    06938
    +0.06%
    HK
    03636
    -2.06%
    AASTOCKS·
    HK
    06938
    +0.06%
    HK
    03636
    -2.06%
    © 2026 Longbridge｜Disclaimer